GlaxoSmithKline plc
Index- P/E17.57 EPS (ttm)2.57 Insider Own- Shs Outstand2.43B Perf Week0.44%
Market Cap109.86B Forward P/E15.16 EPS next Y2.98 Insider Trans- Shs Float2.40B Perf Month4.51%
Income6.27B PEG- EPS next Q- Inst Own10.60% Short Float0.18% Perf Quarter1.51%
Sales35.56B P/S3.09 EPS this Y22.50% Inst Trans-0.17% Short Ratio1.15 Perf Half Y-4.28%
Book/sh3.20 P/B14.11 EPS next Y-1.16% ROA10.40% Target Price46.69 Perf Year-8.60%
Cash/sh2.61 P/C17.29 EPS next 5Y-15.00% ROE67.60% 52W Range41.25 - 54.46 Perf YTD5.66%
Dividend2.45 P/FCF- EPS past 5Y4.70% ROI24.90% 52W High-17.08% Beta0.62
Dividend %5.43% Quick Ratio0.70 Sales past 5Y1.70% Gross Margin69.40% 52W Low9.48% ATR0.61
Employees99451 Current Ratio1.00 Sales Q/Q-10.00% Oper. Margin24.30% RSI (14)61.24 Volatility1.18% 1.33%
OptionableYes Debt/Eq3.76 EPS Q/Q-58.30% Profit Margin17.90% Rel Volume0.80 Prev Close44.99
ShortableYes LT Debt/Eq2.70 Earnings- Payout90.80% Avg Volume3.84M Price45.16
Recom2.80 SMA203.93% SMA502.15% SMA200-5.52% Volume3,084,800 Change0.38%
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-28-13Upgrade Deutsche Bank Hold → Buy
Jan-11-11Upgrade Jefferies Hold → Buy
Jun-02-10Upgrade Jefferies Hold → Buy
Feb-16-10Upgrade JP Morgan Underweight → Neutral $26
Jan-13-10Downgrade Credit Suisse Outperform → Underperform
Nov-24-09Initiated Leerink Swann Mkt Perform
Nov-16-09Initiated Deutsche Securities Hold
Nov-12-09Initiated Barclays Capital Equal Weight
Oct-23-09Downgrade Jefferies & Co Buy → Hold
Mar-17-09Initiated Credit Suisse Outperform
Jan-26-09Initiated Jefferies & Co Buy
Nov-14-08Downgrade UBS Buy → Neutral
Apr-18-08Downgrade JP Morgan Neutral → Underweight
Feb-11-08Upgrade UBS Neutral → Buy
Feb-01-08Upgrade HSBC Securities Underweight → Neutral
Oct-24-07Initiated Bernstein Mkt Perform
Sep-06-07Initiated UBS Neutral
Jul-25-07Downgrade Bear Stearns Peer Perform → Underperform
Jan-28-15 12:40PM  The $25B GSK-Novartis deal clears major hurdle at American City Business Journals
12:00PM  Novartis (NVS) Up on Earnings and Revenue Beat in Q4 - Analyst Blog Zacks
Jan-26-15 05:10PM  Pfizer's Prevenar 13 Wins CHMP Backing for Expanded Use - Analyst Blog Zacks
09:17AM  GSK expands its portfolio of medicines in the US for patients with asthma and COPD PR Newswire
Jan-23-15 05:50PM  Will Novartis' (NVS) Earnings Disappoint Expectations in Q4? - Analyst Blog Zacks
04:06PM  Pharmaceutical industry supply chain Market Realist
08:35AM  GSK-Parexel partnership takes first steps following layoffs announcement at American City Business Journals
08:10AM  Box starts trading and Ubers back in Delhi5 things to know today at Fortune
07:42AM  Glaxo tackles fight against Ebola CNBC
Jan-21-15 06:03PM  Investment Bets On Antibiotics To Help Invigorate Investor Portfolios at Forbes
08:35AM  Africa's Consumer Economy at Forbes
Jan-20-15 02:05PM  Stocks: Why earnings matter? CNBC
07:00AM  GlaxoSmithKline, plc (GSK): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Jan-16-15 01:50PM  OncoMed Starts Expansion Stage Study for Solid Tumor Drug - Analyst Blog Zacks
Jan-15-15 05:00PM  Isis Pharmaceuticals Earns Milestone Payment from Biogen - Analyst Blog Zacks
10:50AM  Vical Up on Deal with AnGes to Develop Ebola Treatment - Analyst Blog Zacks
Jan-12-15 02:49AM  More Rotavirus Vaccination Means Less Rotavirus at Forbes
Jan-11-15 06:22PM  Shire to buy NPS for $5.2 billion at USA TODAY
Jan-06-15 11:01AM  Gardasil HPV Vaccine Not Linked To Multiple Sclerosis Or Related Diseases at Forbes
Jan-05-15 06:20PM  Hot Biotech Stocks: Isis, Kite Jump On Big Deals at Investor's Business Daily
01:17PM  Isis Pharma To Develop GI Drugs With J&J at Investor's Business Daily
09:05AM  The 2015 Forecast: Another Year To Thrive at Forbes
08:15AM  Chuck Norris Attacks The Pharmaceutical Industry at Forbes
Dec-31-14 05:16PM  Pfizer, Home of Lipitor and Viagra, Lifts Dividend at Investor's Business Daily
01:24PM  CDC warns on flu epidemic CNBC
Dec-30-14 10:00AM  Are Placebos Ethical In Ebola Trials? at Forbes
Dec-29-14 10:38AM  Emerald of the Equator: Indonesia the Next Healthcare Frontier at Forbes
Dec-26-14 12:05PM  BioCryst Hits Trifecta For Flu, Ebola, and Hereditary Angioedema at Forbes
Dec-24-14 10:34AM  Alibaba's Attack On Counterfeits; As I've Said Before, Leave Forgeries To The Market at Forbes
07:02AM  Tis the season for buying stocks dumped for tax reasons at MarketWatch
Dec-23-14 04:11PM  BioMarin CEO Sees Big Future For Prosensa Drug at Investor's Business Daily
Dec-19-14 06:49AM  The Ebola Treatment You Haven't Heard Of at Forbes
Dec-18-14 03:11PM  GlaxoSmithKline (GSK) Stock Rises Today on Positive Experimental Shingles Vaccine Trial Results at TheStreet
07:59AM  Glaxo Says Dividend Is Secure as Analysts Question Payout at Bloomberg
07:00AM  Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant GlobeNewswire
Dec-12-14 04:03PM  HFF closes sale of BioMed Realty Trust life sciences facility in Rockville, Maryland Thomson Reuters ONE
Dec-11-14 09:35PM  Stock pro Bhansali: Opportunity abroad in '15 at USA TODAY
03:29PM  Newest HPV Vaccine Protects Against 9 Strains at Forbes
Dec-10-14 08:28AM  GSK Changes Its Drug Sales Practices And R&D Suffers at Forbes
Dec-09-14 07:00AM  How to Trade Foreign Stocks Without Leaving the U.S. Morningstar
Dec-04-14 05:32PM  British drugmaker cutting hundreds of US jobs AP
02:00PM  Array BioPharma Regains Binimetinib Rights from Novartis Zacks
11:29AM  Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative PR Newswire
10:00AM  Mylan receives tentative FDA approval for pediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative PR Newswire
Dec-03-14 05:24PM  Rare disease biotech deal CNBC
01:54PM  Glaxo Reorganization to Shift Lots of R&D Work out of North Carolina at The Wall Street Journal
01:52PM  [$$] GlaxoSmithKline to Lay Off Hundreds of U.S. Employees at The Wall Street Journal
Dec-01-14 04:20PM  Dynavax Regains TLR 7/9 Inhibitor DV1179 Rights from Glaxo Zacks
12:31PM  Glaxo Is Said Near Announcing Reorganization, Job Cuts at Bloomberg
12:17PM  Glaxo Plans Hundreds of Layoffs in the U.S. as Part of a Reorganization at The Wall Street Journal
09:24AM  Oil stocks volatile; GlaxoSmithKline job cuts may be in the works; Lions Gate in talks with Chinese conglomerate Hot Stock Minute
08:02AM  American Airlines, Stone Energy, GlaxoSmithKline, Merck and NewLink Genetics highlighted as Zacks Bull and Bear of the Day Zacks
07:34AM  Stocks Fall; Oil prices rebound; Black Friday sales slide Hot Stock Minute
Nov-30-14 07:00PM  GSK to ax US jobs as part of $1.6B cost cuts CNBC
Nov-28-14 10:49AM  Glaxo's Ebola Candidate Well-Tolerated in Early U.S. Study Zacks
Nov-27-14 07:06PM  GlaxoSmithKline fires executive who raised race complaint in South Africa: Bloomberg Reuters
07:04PM  GlaxoSmithKline fires executive who raised race complaint in South Africa -Bloomberg Reuters
04:13PM  Glaxo Fires Executive Who Raised South Africa Race Complaint at Bloomberg
03:30AM  Ebola Vaccine: GlaxoSmithKline Trial Found Safe at Bloomberg
Nov-26-14 07:01PM  GlaxoSmithKline Ebola Vaccine Found Safe in Early Tests at Bloomberg
02:24PM  Novartis to Divest Nicotine Patch Habitrol at The Wall Street Journal
12:30PM  AstraZeneca's (AZN) Respiratory Drug Approved in the EU Zacks
Nov-24-14 03:57PM  Merck, Iowa firm sign Ebola vaccine licensing deal AP
10:57AM  Buying Glaxo's Biotech Stock Throwbacks Proves Profitable Yahoo Finance Blogs
10:22AM  BioMarin Buys Prosensa Backs Up Troubled Drug at Investor's Business Daily
03:51AM  GSK shareholders to vote on Novartis deal on Dec. 18 Reuters
Nov-19-14 12:24PM  Sanofi's case for experimental drugs in pipeline at CNBC
Nov-18-14 07:35PM  The Top Performing And Yielding Dividend Funds at Investor's Business Daily
01:04PM  Good News From A Failed Digital Health Randomized Clinical Trial: It Was Performed at Forbes
Nov-14-14 03:00AM  Europe shares open higher with positive GDP figures CNBC
Nov-13-14 08:31AM  Is A Boston University Professor's Plan For Lower Drug Costs Viable? at Forbes
Nov-12-14 03:14PM  Ebola To Have A Global Burden Of $5.9 Billion By End Of 2016 at Forbes
Nov-11-14 11:52AM  Aegerion to Acquire Myalept, Boost Portfolio - Shares Up Zacks
11:33AM  Insys Q3 Beats Estimates, Helping Stock Rebound at Investor's Business Daily
Nov-10-14 08:34AM  The Inaccurate And Unfair WHO Attack On Pharma Ebola Efforts at Forbes
Nov-06-14 12:01PM  FTSE ends higher after ECB hints at stimulus at MarketWatch
Nov-05-14 08:15AM  Ebola Is A Symptom Of Our Compounding Failures at Forbes
Nov-04-14 11:02AM  Bill Gates-Backed Group Weighs Funding for Ebola Vaccine at Bloomberg
Oct-29-14 08:59AM  Dear Sanofi: Firing CEO Chris Viehbacher Is A Huge Mistake at Forbes
Oct-28-14 09:37PM  After merger, where's Walgreen Boots Alliance headed? CNBC
03:31PM  In Ebola Crisis, New Vaccine Candidates Show Uncertain Promise at Forbes
10:07AM  Ebola: The making of a $1 billion drug at
06:12AM  Novartis' precision M&A plan: CEO CNBC
Oct-27-14 06:48PM  The Ebola Crisis In 3 Charts And 3 Articles at Forbes
01:38PM  Will Novartis (NVS) Disappoint in Q3 Earnings Season? Zacks
Oct-26-14 02:59PM  Drugmakers bet on Ebola vaccines, treatments at USA TODAY
Oct-24-14 09:51AM  J&J and Glaxo Ready to Collaborate for Ebola Vaccine Work Zacks
08:35AM  Glaxo Gains on Q3 Earnings Beat and Restructuring Plans Zacks
Oct-23-14 11:44PM  Head of GSK Ebola Vaccine Research: "Can We Even Consider Doing A Trial?" at Forbes
01:38PM  Drugmakers want indemnity CNBC
12:51AM  [$$] GlaxoSmithKline Unveils Cost-Saving Plan, Considers IPO of HIV Business at The Wall Street Journal
Oct-22-14 04:30PM  Stocks Erase Gains to End Lower Morningstar
11:57AM  Alibaba bounces back, Six Flags riding high and Glaxo to tackle Ebola Yahoo Finance
11:30AM  Stocks Move Higher Again After Earnings Morningstar
10:23AM  Glaxo Considers ViiV IPO to Capitalize on HIV-Drug Sales at Bloomberg
09:38AM  Europe shares fluctuate on ECB rumors; BAT falls at CNBC
09:14AM  GlaxoSmithKline moving forward with Ebola vaccine at Fortune
08:46AM  Why GlaxoSmithKline (GSK) Stock Is Up Today at TheStreet
07:55AM  [$$] Glaxo Third-Quarter Earnings Beat Expectations at The Wall Street Journal
07:48AM  GSK CEO and CFO Interviewed on 2014 Q3 Results PR Newswire
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. The company's total wellness products comprise Panadol for the treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; and ENO Tums, a rapid relief antacid. Its oral care products include Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. The company's nutrition products comprise Horlicks and Maxinutrition for nutrition; and skin health products include Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases. The company has a strategic cancer immunotherapy collaboration with Adaptimmune Limited to develop and commercialize NY-ESO-1 clinical cancer program. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerAug 11Buy3912271.66172,651675,457,614,37130,748,723Aug 11 04:55 PM
GLAXOSMITHKLINE PLC10% OwnerMay 09Buy8544835.30317,7702,715,292,313,28130,576,072May 13 04:43 PM
GLAXOSMITHKLINE PLC10% OwnerApr 01Buy12.00103,7621,245,1441,989,598Apr 02 12:42 PM
GLAXOSMITHKLINE PLCFormer 10% OwnerFeb 19Buy14.0035,000490,0001,356,533Feb 20 06:56 PM
GLAXOSMITHKLINE PLC10% OwnerFeb 11Buy12850698.95342,2294,397,881,850,96030,258,302Feb 13 04:41 PM
GLAXOSMITHKLINE PLCFormer 10% ShareholderFeb 10Buy12.00143,7731,725,276143,773Feb 12 05:56 PM